Novel products for haemostasis. - Wikidata - wikimedia - TriplyDB

Novel products for haemostasis.

Novel products for haemostasis.

http://www.wikidata.org/entity/Q38206850

about

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Longer-acting clotting factor concentrates for hemophilia.Safety surveillance in haemophilia and allied disorders.

P2860

Q37185097-88E9B9BF-1908-49DD-AE57-9EC5C3CF7C0A Q38543283-68FF64A6-3C9C-4D08-A846-55AE68C336B0 Q38784133-A1D22B87-2360-49E8-8A6A-608F0FCD40A8

P2860

Novel products for haemostasis.

http://www.wikidata.org/entity/Q38206850

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel products for haemostasis.

@en

type

label

Novel products for haemostasis.

@en

prefLabel

Novel products for haemostasis.

@en

P1433

Q38206850-76E318A6-BA08-461C-BCCC-95665D3DEC5A

P1476

Q38206850-AD3D0F15-4612-4E24-AB27-63CDF84E8E6A

P2093

Q38206850-097D8DEB-5013-44CA-9CF7-68A3312AA1D2

Q38206850-B346991A-98B4-496E-8067-8932AF53F6E8

Q38206850-E7BD1D6E-F8D9-41E4-9321-4AE0D80D35F1

P2860

Q38206850-0A0AFB7E-F0CE-49A7-B43C-FAA3AAAFA98F

Q38206850-0DAF7FF9-17E2-4155-A4A5-FB58FEB8F6FE

Q38206850-11094D4A-F506-453D-BE42-F3FCE71FEA1B

Q38206850-1CE8090F-AC17-4AA7-A69A-6C5D624CDB57

Q38206850-3E431032-5AAA-44F9-A88C-8E52EEBC4EC7

Q38206850-3E90F5CF-E183-4B6D-8A41-1EC9D105B1D9

Q38206850-43671B44-824D-4718-8D42-B3D378F55CB7

Q38206850-60A374CD-087C-4666-B953-4244016D5075

Q38206850-6786984B-3151-49F4-BEA5-C337BC8ABC91

Q38206850-7108F677-ABDB-43BC-A45D-07854BC8B654

P304

Q38206850-5181C957-73EF-4E1D-A6CE-F7A0972C007D

P31

Q38206850-F193A4FD-A94B-4840-A296-28408A36CCEB

P356

Q38206850-135D6319-0016-4A0C-B1D7-68E688CDFF80

P478

Q38206850-0FF7050F-206D-443E-90ED-FE8019C2DE9B

P577

Q38206850-232A6F6A-A566-4924-A921-AA0332DA10D9

P5875

Q38206850-7110DEC9-BDFE-4141-87C5-783BAA0A35F0

P698

Q38206850-3FC31DEB-5EC9-4F55-9CF9-77CFACB1EC5A

P356

P1433

P1476

Novel products for haemostasis.

@en

P2093

C Hermans

http://www.w3.org/2001/XMLSchema#string

M Shima

http://www.w3.org/2001/XMLSchema#string

P de Moerloose

http://www.w3.org/2001/XMLSchema#string

P2860

Future of coagulation factor replacement therapy

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity

Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.

How we choose factor VIII to treat hemophilia.

The challenge of biosimilars.

Molecular approaches for improved clotting factors for hemophilia.

Modern haemophilia care.

Advances in the treatment of inherited coagulation disorders.

Purchasing factor concentrates in the 21st century through competitive tendering.

P304

29-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.12413

http://www.w3.org/2001/XMLSchema#string

P478

20 Suppl 4

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261924118

http://www.w3.org/2001/XMLSchema#string

P698

24762272

http://www.w3.org/2001/XMLSchema#string